Loading...
XSTO
BACTIb
Market cap118mUSD
Jun 09, Last price  
30.60SEK
Name

Bactiguard Holding AB

Chart & Performance

D1W1MN
P/E
P/S
4.43
EPS
Div Yield, %
Shrs. gr., 5y
1.02%
Rev. gr., 5y
7.20%
Revenues
262m
+28.38%
127,010,000117,516,0004,382,000129,005,000126,733,000109,047,000131,420,000118,736,000147,458,000150,097,000184,987,000172,315,000169,486,000223,560,000203,990,000261,878,000
Net income
-30m
L-78.45%
7,669,000-24,750,000-15,305,000-38,359,000-3,407,000-95,042,000-26,501,000-26,851,000-3,251,000-14,931,00016,256,000-38,389,000-58,773,000-52,877,000-138,382,000-29,815,000
CFO
25m
P
79,764,00056,714,000-2,680,000-40,916,000-45,070,000-35,743,000-20,791,000-12,411,0006,117,000-16,691,00053,982,000702,0007,256,0003,062,000-52,331,00024,989,000
Earnings
Jul 14, 2025

Profile

Bactiguard Holding AB (publ), a medical device company, engages in the development and supply of infection prevention solutions in Sweden and internationally. Its infection prevention solutions reduce the risk of healthcare associated infections and the use of antibiotics. The company's products portfolio of urinary catheters, endotracheal tubes, and central venous catheters reduces the risk of infections in the urinary tract, the respiratory tract, and the bloodstream. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter and BIP Endotracheal Tube, which reduces the risk of biofilm formation and infection; BIP Endotracheal Tube Evac, a tube that combines the subglottic secretion drainage with coating to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that offers surveillance and infection prevention. The company's products also include Bactiguard Wound Care and Hydrocyn aqua advanced wound care, a wound wash, debridement, and irrigation solution for acute, chronic, and infected wounds; surgical sutures comprise non-absorbable, natural absorbable, synthetic absorbable, and specialty sutures; VigiMesh, a sterile, non-absorbable, and knitted polypropylene monofilament mesh material for tissue reinforcement used in hernia repair; and Hydrocyn aqua advanced disinfectant, a non-alcoholic disinfectant for skin and surfaces to kill bacteria, virus, and fungi. In addition, it offers ZNN Bactiguard, an orthopedic trauma implants with infection prevention technology; and Aniocyn, a wound and skin care products for dogs, cats, horses, and other pets. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.
IPO date
Jun 19, 2014
Employees
220
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
261,878
28.38%
203,990
-8.75%
223,560
31.90%
Cost of revenue
35,969
68,978
158,925
Unusual Expense (Income)
NOPBT
225,909
135,012
64,635
NOPBT Margin
86.26%
66.19%
28.91%
Operating Taxes
(6,769)
(8,772)
(6,978)
Tax Rate
NOPAT
232,678
143,784
71,613
Net income
(29,815)
-78.45%
(138,382)
161.71%
(52,877)
-10.03%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
187,073
190,793
10,915
Long-term debt
97,568
96,836
287,218
Deferred revenue
149,583
Other long-term liabilities
5,257
5,284
(179,265)
Net debt
167,914
143,708
99,096
Cash flow
Cash from operating activities
24,989
(52,331)
3,062
CAPEX
(14,781)
(7,189)
(10,918)
Cash from investing activities
(14,781)
(8,609)
(10,918)
Cash from financing activities
(21,198)
(11,835)
(13,892)
FCF
221,656
182,595
85,490
Balance
Cash
116,727
123,217
197,727
Long term investments
20,704
1,310
Excess cash
103,633
133,722
187,859
Stockholders' equity
(606,462)
(576,647)
(434,971)
Invested Capital
1,167,828
1,168,208
1,139,697
ROIC
19.92%
12.46%
6.19%
ROCE
40.24%
22.82%
8.80%
EV
Common stock shares outstanding
35,044
35,044
35,044
Price
35.30
-42.88%
61.80
-44.02%
110.40
-33.09%
Market cap
1,237,053
-42.88%
2,165,712
-44.02%
3,868,845
-33.09%
EV
1,404,967
2,309,420
3,967,941
EBITDA
264,164
174,614
113,875
EV/EBITDA
5.32
13.23
34.84
Interest
15,566
13,528
8,697
Interest/NOPBT
6.89%
10.02%
13.46%